RETROSPECTIVE JAPANESE REAL WORLD STUDY OF METASTATIC RENAL CELL CARCINOMA TREATED WITH NIVOLUMAB PLUS IPILIMUMAB (J-cardinal study) - J-cardinal study

Ono Pharmaceutical CO.,LTD. Bristol-Myers Squibb K.K.0 个研究点目标入组 45 人开始时间: 2019年2月22日最近更新: 2023年10月17日

适应症

试验速览

阶段: 未知
状态: 已完成
发起方
入组人数: 45

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

The effectiveness of nivolumab plus ipilimumab combination therapy in a real world setting in Japan at 2-year analysis and safety at 1-year analysis were comparable with those of CheckMate 214. The analysis also demonstrated the effectiveness of second-line therapy after the combination therapy.

研究设计

研究类型: Observational

入排标准

年龄范围: 20years-old 至 ot applicable（—）
性别: All

入选标准

未提供

排除标准

•Patients who are applied for post marketing study of nivolumab plus ipilimumab Favorable on the IMDC risk definition

研究者

发起方

Ono Pharmaceutical CO.,LTD. Bristol-Myers Squibb K.K.

相似试验

已完成

不适用

A Real-World Study of Ipilimumab Treatment After Nivolumab Treatment in Melanoma in JapanMelanoma

NCT03165422Bristol-Myers Squibb68

已完成

2 期

Phase 2 Study of Ipilimumab in Japanese Advanced Melanoma PatientsMelanoma

NCT01990859Bristol-Myers Squibb20

未知

2 期

Japan/Korea Joint Phase II Study of Nimotuzumab plus Irinotecan in Patients with Advanced or Recurrent Gastric CancerAdvanced or Recurrent Gastric Cancer Refractory to 5-fluorouracil-containing Regimens

JPRN-jRCT2080220818DAIICHISANKYO Co.,Ltd.80

终止

3 期

Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction CancerGastroesophageal Junction CancerGastric Cancer

NCT01813253Kuhnil Pharmaceutical Co., Ltd.400

未知

2 期

Phase 2 Study of Ipilimumab in Japanese Advanced Melanoma PatientsMelanoma

JPRN-jRCT2080222335Bristol-Myers K.K.18